[go: up one dir, main page]

WO2002048191A3 - Inhibitory agents derived from specific growth factors - Google Patents

Inhibitory agents derived from specific growth factors Download PDF

Info

Publication number
WO2002048191A3
WO2002048191A3 PCT/IL2001/001143 IL0101143W WO0248191A3 WO 2002048191 A3 WO2002048191 A3 WO 2002048191A3 IL 0101143 W IL0101143 W IL 0101143W WO 0248191 A3 WO0248191 A3 WO 0248191A3
Authority
WO
WIPO (PCT)
Prior art keywords
derived
neuregulin
agents
agent
morphogenetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2001/001143
Other languages
French (fr)
Other versions
WO2002048191A2 (en
Inventor
Benjamin Geiger
Alexander Bershadsky
Alexander Chausovsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Priority to AU2002222471A priority Critical patent/AU2002222471A1/en
Publication of WO2002048191A2 publication Critical patent/WO2002048191A2/en
Anticipated expiration legal-status Critical
Publication of WO2002048191A3 publication Critical patent/WO2002048191A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Inhibitory agents for blocking proliferative, apoptic, mitogenic and morphogenetic processes which are derived from specific growth factors, and in particular to such agents which are derived from specific growth gactors, and in particular to such agents which are derived from NDF (neuregulin). The inhibitory agents of the present invention are optionally and preferably peptides, or homologues, analogues or other related biologically active agents thereof, which are derived from at least a portion of neuregulin. More preferably, such an agent is derived from a particular fragment of neuregulin, known as the ED fragment, which includes the EGF-like domain of neuregulin. Alternatively, the agent is derived from any portion of neuregulin having the ability to bind to at least one of the ErbB-3 and ErbB-2 receptors, but lacking the ability to induce morphogenetic events. Alternatively or additionally, the agent is derived from two or more separate portions of neuregulin having these characteristics. Thus, the inhibitory agent of the present invention only causes a partial phenotypic response, but blocks the ability of full-length neuregulin to induce those aspects of the full response which are related to morphogenetic events, such as cell motility and morphogenetic behaviors
PCT/IL2001/001143 2000-12-11 2001-12-11 Inhibitory agents derived from specific growth factors Ceased WO2002048191A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002222471A AU2002222471A1 (en) 2000-12-11 2001-12-11 Inhibitory agents derived from specific growth factors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25415300P 2000-12-11 2000-12-11
US60/254,153 2000-12-11

Publications (2)

Publication Number Publication Date
WO2002048191A2 WO2002048191A2 (en) 2002-06-20
WO2002048191A3 true WO2002048191A3 (en) 2003-12-11

Family

ID=22963127

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2001/001143 Ceased WO2002048191A2 (en) 2000-12-11 2001-12-11 Inhibitory agents derived from specific growth factors

Country Status (2)

Country Link
AU (1) AU2002222471A1 (en)
WO (1) WO2002048191A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003101401A2 (en) 2002-06-03 2003-12-11 Chiron Corporation Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
WO2007021853A2 (en) * 2005-08-12 2007-02-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neuregulin1-stimulated cell adhesion and cell migration
US20070213264A1 (en) * 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
WO2010060265A1 (en) 2008-11-28 2010-06-03 Zensun (Shanghai) Science & Technology Limited Neuregulin peptides and their use
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
BR112015029293A2 (en) 2013-05-22 2018-04-24 Zensun Shanghai Science & Tech Ltd method and kit for preventing, treating or delaying a cardiovascular disease or disorder in a mammal

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136558A (en) * 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136558A (en) * 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHAUSOVSKY A. ET AL: "Morphogenetic activity of neuregulin requires interactions of neuregulin and its receptor ErbB-3 with heparan sulfate proteoglycans", MOL. BIOL. CELL, vol. 11, no. supplement, 9 December 2000 (2000-12-09), pages 145a, XP009003063 *
CHAUSOVSKY ALEXANDER ET AL: "Morphogenetic effects of neuregulin (Neu differentiation factor) in cultured epithelial cells.", MOLECULAR BIOLOGY OF THE CELL, vol. 9, no. 11, November 1998 (1998-11-01), pages 3195 - 3209, XP002226535, ISSN: 1059-1524 *

Also Published As

Publication number Publication date
AU2002222471A1 (en) 2002-06-24
WO2002048191A2 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
IL134042A0 (en) Modified dorsal tissue affecting factor and compositions
PT1091975E (en) NEW CYCLOSPORINE WITH AN IMPROVED ACTIVITY PROFILE
WO2003031464A3 (en) Remodeling and glycoconjugation of peptides
AU1565300A (en) Anti-germinating method for tubers and bulbs using eugenol and/or isoeugenol
WO2000023094A3 (en) Methods of inhibiting platelet activation and recruitment
MA26337A1 (en) MIXTURES OF CYCLOSPORIN ANALOGS AND THEIR USE AS IMMUNOMODULATORS.
WO2000023039A3 (en) Recombinant hair treatment compositions
PT1181035E (en) CYCLOSPORINE COMPOSITIONS SUBSTANTIALLY OIL-FREE
DE69906345D1 (en) COMPOSITION FOR TREATING AND PREVENTING NEUROLOGICAL AND PATHOPSYCHOLOGICAL DISEASES
DK0984982T3 (en) LH-RH peptide analogues, their use and pharmaceutical compositions containing them
NZ503308A (en) Alpha-ketoamide multicatalytic protease inhibitors
IL156262A0 (en) Anti-cd28 antibodies having no mitogenic activity and pharmaceutical compositions containing the same
MY129668A (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
WO2002048191A3 (en) Inhibitory agents derived from specific growth factors
ES2180948T3 (en) PEPTIDE THAT COMES FROM A SOLUBLE FORM OF ACETILCOLINESTERASE, ACTIVE AS A CHANNEL MODULATOR.
BR0015980A (en) Agent for prophylaxis or treatment of glaucoma, and, use of an angiotensin ii antagonist
WO2002096936A3 (en) Daptomycin and related analogs in crystalline form, their preparation and use
WO1999038532A3 (en) Methods for the prevention and treatment of fibrosis and sclerosis
IL112557A0 (en) Peptides that are vip antagonists and pharmaceutical compositions comprising them
IL143093A0 (en) Topical compositions comprising ascomycins
WO2001027154A3 (en) Membrane translocating peptide drug delivery system
WO2002039118A8 (en) Screening methods for bone morphogenetic mimetics
EP1031352A3 (en) Use of desmopressin in the preparation of a metastatic dissemination inhibitor medicament during cancer surgery
WO2001095946A3 (en) Combination product for carrying out a cytotoxic treatment in a mammal
WO2001055176A3 (en) Methods for inhibiting smooth muscle cell proliferation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DE DK DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP